AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30646923 — intervention group
Group type: EXPERIMENTAL
Intervention: Program of Social intervention associated with techniques of Domotic and Remote assistance
Number of subjects: 0
Study 30646923 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 0
Study 29246424 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass (Biogran) alone (group 1)
Number of subjects: 33
Study 29246424 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass combined with autogenous bone graft (1:1) (group 2)
Number of subjects: 33
Study 29246424 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft alone (group 3)
Number of subjects: 33
Study 29246424 — intervention group
Group type: COMPARATOR
Intervention: Bioactive glass and autogenous bone graft (1:1)
Number of subjects: 33
Study 29246424 — intervention group
Group type: COMPARATOR
Intervention: Bioactive glass alone and autogenous bone graft alone
Number of subjects: 33
Study 27639163 — intervention group
Group type: EXPERIMENTAL
Intervention: WM training (20 sessions of dual n-back task training for four weeks)
Number of subjects: 34
Study 25275522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-social priming
Number of subjects: 45
Study 25275522 — intervention group
Group type: COMPARATOR
Intervention: Non-social priming
Number of subjects: 45
Study 25275522 — intervention group
Group type: COMPARATOR
Intervention: Anti-social priming
Number of subjects: 45
Study 21952418 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intervention
Number of subjects: 33
Study 21952418 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 33
Study 21952418 — intervention group
Group type: COMPARATOR
Intervention: Six minute walk test
Number of subjects: 33
Study 21952418 — intervention group
Group type: COMPARATOR
Intervention: Endurance shuttle walk test
Number of subjects: 33
Study 20398993 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator patients
Number of subjects: 12
Study 20398993 — intervention group
Group type: COMPARATOR
Intervention: Actor patients
Number of subjects: 12
Study 18640933 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (bolus and infusion fluorouracil [FU] and leucovorin [LV] with oxaliplatin)
Number of subjects: 373
Study 18640933 — intervention group
Group type: EXPERIMENTAL
Intervention: bFOL (bolus FU and low-dose LV with oxaliplatin)
Number of subjects: 373
Study 18640933 — intervention group
Group type: EXPERIMENTAL
Intervention: CapeOx (capecitabine with oxaliplatin)
Number of subjects: 373
Study 18640933 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus bevacizumab
Number of subjects: 373
Study 18640933 — intervention group
Group type: EXPERIMENTAL
Intervention: bFOL plus bevacizumab
Number of subjects: 373
Study 18640933 — intervention group
Group type: EXPERIMENTAL
Intervention: CapeOx plus bevacizumab
Number of subjects: 373
Study 18640933 — intervention group
Group type: EXPERIMENTAL
Intervention: All treated patients
Number of subjects: 373
Study 16447879 — intervention group
Group type: EXPERIMENTAL
Intervention: Large dosage of salvia injection (24 ml)
Number of subjects: 120
Study 16447879 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle dosage of salvia injection (16 ml)
Number of subjects: 120
Study 16447879 — intervention group
Group type: EXPERIMENTAL
Intervention: Small dosage of salvia injection (8 ml)
Number of subjects: 120
Study 16447879 — intervention group
Group type: COMPARATOR
Intervention: Control group (no salvia injection)
Number of subjects: 120
Study 16447879 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall efficacy of salvia injection
Number of subjects: 120
Study 12005271 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 6.25 mg
Number of subjects: 1791
Study 12005271 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 1791
Study 12005271 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 1791
Study 12005271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1791
Study 19667506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 0
Study 19667506 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylureas, repaglinide, metformin, acarbose, thiazolidinediones
Number of subjects: 0
Study 8979780 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM (omeprazole 20 mg daily, amoxycillin 500 mg tid, metronidazole 400 mg tid)
Number of subjects: 80
Study 8979780 — intervention group
Group type: EXPERIMENTAL
Intervention: RAM (ranitidine 600 mg bd, amoxycillin 500 mg tid, metronidazole 400 mg tid)
Number of subjects: 80
Study 8979780 — intervention group
Group type: EXPERIMENTAL
Intervention: OC (omeprazole 20 mg daily, clarithromycin 500 mg tid)
Number of subjects: 80
Study 8979780 — intervention group
Group type: COMPARATOR
Intervention: OP (omeprazole 20 mg daily and placebo)
Number of subjects: 80
Study 1279170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iloprost (0.5-2.0 ng/kg/min)
Number of subjects: 35
Study 1279170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 35
Study 3888335 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cytotoxic portal vein perfusion
Number of subjects: 244
Study 3888335 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 244
Study 31050786 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational attainment (EA)
Number of subjects: 23468
Study 31050786 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma exposure
Number of subjects: 23468
Study 31050786 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-taking behaviors
Number of subjects: 23468
Study 31050786 — intervention group
Group type: EXPERIMENTAL
Intervention: Income (Mendelian randomization)
Number of subjects: 23468
Study 31050786 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable MR income
Number of subjects: 23468
Study 31050786 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable MR EA
Number of subjects: 23468
Study 28812132 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Restriction-Group (DR)
Number of subjects: 95
Study 28812132 — intervention group
Group type: COMPARATOR
Intervention: No-Diet-Restriction-Group (NDR)
Number of subjects: 95
Study 27243567 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Processing Therapy‐Cognitive Only Version
Number of subjects: 108
Study 27243567 — intervention group
Group type: COMPARATOR
Intervention: Group Present‐Centered Therapy
Number of subjects: 108
Study 27243567 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who no longer met criteria for PTSD following treatment
Number of subjects: 108
Study 27243567 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep medication use
Number of subjects: 108
Study 25903448 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 33
Study 25903448 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Exercise (BE)
Number of subjects: 33
Study 25903448 — intervention group
Group type: COMPARATOR
Intervention: Comparison between AE and BE
Number of subjects: 33
Study 23930342 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing programme
Number of subjects: 209
Study 23930342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no academic detailing)
Number of subjects: 209
Study 20603813 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for measurement error in biomarkers
Number of subjects: 0
Study 20603813 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from an osteoporosis clinical study
Number of subjects: 0
Study 18006026 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 60
Study 15705230 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyc‐o‐Mato((R)) drink (250 ml daily providing about 6 mg lycopene, 4 mg phytoene, 3 mg phytofluene, 1 mg beta‐carotene, and 1.8 mg alpha‐tocopherol)
Number of subjects: 26
Study 15705230 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 26
Study 12849805 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring with both serum E(2) and ultrasound findings
Number of subjects: 297
Study 12849805 — intervention group
Group type: COMPARATOR
Intervention: Monitoring with ultrasound alone
Number of subjects: 297
Study 10369848 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (160 to 320 mg per day)
Number of subjects: 302
Study 10369848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 7725845 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (CT) treatment with 100 IU and 250 mg calcium 3 times a week
Number of subjects: 24
Study 7725845 — intervention group
Group type: COMPARATOR
Intervention: Routine thalassemia therapy (Control)
Number of subjects: 24
Study 2202804 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.5 mg/kg, then 0.20 mg/kg, every 12 hours)
Number of subjects: 185
Study 2202804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 2202804 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 185
Study 7032343 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray 200 micrograms b.i.d.
Number of subjects: 29
Study 7032343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30326770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (iOT)
Number of subjects: 118
Study 30326770 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 118
Study 28669111 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 50
Study 28669111 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 50
Study 28669111 — intervention group
Group type: COMPARATOR
Intervention: Gastrografin
Number of subjects: 50
Study 28669111 — intervention group
Group type: COMPARATOR
Intervention: Barium sulfate
Number of subjects: 50
Study 24819432 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy program (MPP) twice a week (G2: n=58)
Number of subjects: 114
Study 24819432 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy program (MPP) three times a week (G3: n=56)
Number of subjects: 114
Study 23969334 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinokitiol-containing gel
Number of subjects: 18
Study 23969334 — intervention group
Group type: COMPARATOR
Intervention: Control gel (not containing hinokitiol)
Number of subjects: 18
Study 21834113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-Directed Anticoagulation Service (PDAS)
Number of subjects: 500
Study 19273704 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 75 mg/m² every 3 weeks for 6 cycles (arm A)
Number of subjects: 132
Study 19273704 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 30 mg/m² per day for 3 consecutive days every 2 weeks for 3 cycles followed by ifosfamide 12.5 g/m² over 5 days every 3 weeks for 3 cycles (arm B)
Number of subjects: 132
Study 19273704 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard-dose doxorubicin)
Number of subjects: 132
Study 17902234 — intervention group
Group type: COMPARATOR
Intervention: Self-etching primer (Transbond Plus) with light-cure adhesive (Transbond XT)
Number of subjects: 240
Study 17902234 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva contamination after priming
Number of subjects: 240
Study 17902234 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva contamination before priming
Number of subjects: 240
Study 17902234 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva contamination before and after priming
Number of subjects: 240
Study 15093571 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic-BMT (Allo-BMT)
Number of subjects: 0
Study 15093571 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous-BMT (A-BMT)
Number of subjects: 0
Study 15093571 — intervention group
Group type: COMPARATOR
Intervention: CCT
Number of subjects: 0
Study 11552108 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed intravenous fluids (IVF)
Number of subjects: 20
Study 11552108 — intervention group
Group type: COMPARATOR
Intervention: Nonwarmed intravenous fluids
Number of subjects: 20
Study 9576140 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskus/Accuhaler (DA)
Number of subjects: 50
Study 9576140 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler (TH)
Number of subjects: 50
Study 7867872 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly thyroxine therapy
Number of subjects: 7
Study 7867872 — intervention group
Group type: COMPARATOR
Intervention: Daily thyroxine therapy
Number of subjects: 7
Study 2678692 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid reconstruction surgery
Number of subjects: 2000
Study 334212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine, 120 mg daily
Number of subjects: 0
Study 31217353 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet
Number of subjects: 0
Study 31217353 — intervention group
Group type: COMPARATOR
Intervention: Moderate-carbohydrate diet
Number of subjects: 0
Study 31217353 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 0
Study 28089729 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation
Number of subjects: 0
Study 28089729 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 0
Study 28089729 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched women without urgency urinary incontinence)
Number of subjects: 0
Study 25605741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab continuation
Number of subjects: 262
Study 25605741 — intervention group
Group type: COMPARATOR
Intervention: No continuation of bevacizumab
Number of subjects: 262
Study 25214451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (n=16)
Number of subjects: 31
Study 25214451 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (n=15)
Number of subjects: 31
Study 22773768 — intervention group
Group type: EXPERIMENTAL
Intervention: HYP(BR) - Beetroot juice delivering 0.07 mmol nitrate/kg body wt/day
Number of subjects: 15
Study 22773768 — intervention group
Group type: COMPARATOR
Intervention: HYP(CON) - Control drink
Number of subjects: 15
Study 19375948 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-breast irradiation (intraoperative radiation therapy)
Number of subjects: 0
Study 19375948 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast radiation therapy
Number of subjects: 0
Study 17970681 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP-D (scaling and root planing with local doxycycline)
Number of subjects: 16
Study 17970681 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 16
Study 14693787 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam irradiation with five fractions of 3 Gy (total dose 15 Gy)
Number of subjects: 34
Study 14693787 — intervention group
Group type: COMPARATOR
Intervention: External beam irradiation with seven fractions of 2 Gy (total dose 14 Gy)
Number of subjects: 34
Study 11452166 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (600 IU/kg) plus IV iron (n = 29)
Number of subjects: 110
Study 11452166 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (600 IU/kg) plus oral iron (n = 29)
Number of subjects: 110
Study 11452166 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus IV iron (n = 25)
Number of subjects: 110
Study 11452166 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus oral iron (n = 27)
Number of subjects: 110
Study 9635707 — intervention group
Group type: COMPARATOR
Intervention: Pelvic radiotherapy alone (45 to 50.4 Gy)
Number of subjects: 204
Study 9635707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy and bolus 5-fluorouracil-based chemotherapy
Number of subjects: 204
Study 7977118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg over 2 minutes, followed by 0.35 mg/kg if needed)
Number of subjects: 37
Study 7977118 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label intravenous diltiazem after placebo
Number of subjects: 37
Study 7977118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 37
Study 7977118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 2600195 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 30 mg
Number of subjects: 6
Study 2600195 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg
Number of subjects: 6
Study 2600195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30940760 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-dose liposomal amphotericin
Number of subjects: 0
Study 30940760 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (WHO recommended first-line treatment)
Number of subjects: 0
Study 27801550 — intervention group
Group type: EXPERIMENTAL
Intervention: Herring diet
Number of subjects: 15
Study 27801550 — intervention group
Group type: COMPARATOR
Intervention: Reference diet (chicken and lean pork)
Number of subjects: 15
Study 26882608 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinying Capsule (JC), 0.5 g per capsule, 4 capsules each time, 3 times per day for 4 weeks
Number of subjects: 328
Study 26882608 — intervention group
Group type: COMPARATOR
Intervention: Kangfuyan Capsule (KC), 0.4 g per capsule, 3 capsules each time, twice per day for 4 weeks
Number of subjects: 328
Study 26882608 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinying Capsule (JC)
Number of subjects: 328
Study 26882608 — intervention group
Group type: COMPARATOR
Intervention: Kangfuyan Capsule (KC)
Number of subjects: 328
Study 24260194 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg once daily
Number of subjects: 29
Study 24260194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 21221982 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate/gonadotropin/antagonist (mild protocol)
Number of subjects: 159
Study 21221982 — intervention group
Group type: COMPARATOR
Intervention: Microdose GnRH agonist flare (group II)
Number of subjects: 159
Study 17964822 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIVA (Ambulatory Conservative Haemodynamic Management of Varicose Veins)
Number of subjects: 150
Study 17964822 — intervention group
Group type: COMPARATOR
Intervention: Saphenous stripping
Number of subjects: 150
Study 17964822 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIVA
Number of subjects: 150
Study 16931262 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 115
Study 16931262 — intervention group
Group type: COMPARATOR
Intervention: Apraclonidine 0.5%
Number of subjects: 115
Study 12635578 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nasal fluticasone (50 micrograms per spray, 2 sprays each side every day)
Number of subjects: 32
Study 12635578 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nasal fluticasone
Number of subjects: 32
Study 12635578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11144832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Handicap Inventory (THI)
Number of subjects: 100
Study 11144832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Questionnaire (TQ)
Number of subjects: 100
Study 11144832 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ sleep subscale
Number of subjects: 100
Study 9570352 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour-derived tissues from colorectal adenocarcinoma patients
Number of subjects: 0
Study 9570352 — intervention group
Group type: COMPARATOR
Intervention: Serum fucose levels in colorectal cancer patients
Number of subjects: 0
Study 9570352 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum fucose levels normalized to total protein in colorectal cancer patients
Number of subjects: 0
Study 9570352 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucose levels in relation to Dukes' classification
Number of subjects: 0
Study 8311273 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA) with high dose of opioid anesthetic, n = 12
Number of subjects: 24
Study 8311273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar Epidural Anesthesia (LEA) to T4 sensory level with light general anesthetic, n = 12
Number of subjects: 24
Study 3418329 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency neuroleptics (haloperidol)
Number of subjects: 0
Study 3418329 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-potency neuroleptics (chlorpromazine or clozapine)
Number of subjects: 0
Study 3418329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31216128 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional/light-cured resin composite (Ceram-X)
Number of subjects: 30
Study 31216128 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-fill/light-cured resin composite (SureFil SDR)
Number of subjects: 30
Study 31216128 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-fill/dual-cured resin composite (Core-X Flow)
Number of subjects: 30
Study 31216128 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC base with resin composites
Number of subjects: 30
Study 31216128 — intervention group
Group type: EXPERIMENTAL
Intervention: No GIC base with resin composites
Number of subjects: 30
Study 31216128 — intervention group
Group type: COMPARATOR
Intervention: Intact teeth
Number of subjects: 30
Study 31216128 — intervention group
Group type: COMPARATOR
Intervention: Unrestored teeth
Number of subjects: 30
Study 28575282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Number of subjects: 88
Study 28575282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Number of subjects: 88
Study 26317629 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Oral Carbohydrate (CHO)
Number of subjects: 134
Study 26317629 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Oral Rehydration Solution (ORS)
Number of subjects: 134
Study 26317629 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study 26317629 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative vasopressor use
Number of subjects: 134